GlassScriptPhysician profile
Warren L Strickland
NPI 1881665032
$10,765.28
in general payments reported to CMS, 2019-2025
39 companies · $2,997 in 2025
The $2,997 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,882 · 2020: $731 · 2021: $823 · 2022: $2,541 · 2023: $754 · 2024: $1,037 · 2025: $2,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,028 · Travel and Lodging: $1,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,028.26 |
| Travel and Lodging | $1,759.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $3,429.32 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Abbott Laboratories | $1,903.98 | 2020-2025 | Navitor, Diamondback Peripheral |
| Novartis Pharmaceuticals Corporation | $1,376.06 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $457.42 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $449.73 | 2019-2025 | Lifevest |
| Amgen INC. | $428.98 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $410.04 | 2021-2025 | Onyx Frontier, Hawkone, In.Pact Admiral |
| Pfizer INC. | $277.98 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $246.76 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $210.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $159.58 | 2019-2025 | Camzyos, Eliquis |
| W. L. Gore & Associates, INC. | $151.93 | 2020 | |
| Sanofi-Aventis U.S. LLC | $126.11 | 2019-2024 | |
| Irhythm Technologies, INC. | $125.43 | 2022-2024 | Zio Monitor, Zio Xt Patch |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.22 | 2019-2025 | Jardiance |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Strickland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.